About
Company Overview
Management Team
Board of Directors
Advisors
Partnering
Careers
CBD
Programs
Overview
Graft versus Host Disease (GVHD)
Acute and Chronic Pain
Additional Preclinical Programs
News
Investors
Investor Overview
Press Releases
Company Information
SEC Filings
Stock Information
Corporate Governance
Contact
About
Company Overview
Management Team
Board of Directors
Advisors
Partnering
Careers
CBD
Programs
Overview
Graft versus Host Disease (GVHD)
Acute and Chronic Pain
Additional Preclinical Programs
News
Investors
Investor Overview
Press Releases
Company Information
SEC Filings
Stock Information
Corporate Governance
Contact
Press Releases
Menu
Overview
Press Releases
Company Information
Stock Information
SEC Filings
Corporate Governance
Recent Press Releases
Kalytera Reports Third Quarter 2018 Financial Results
November 30, 2018
Kalytera Announces Next Share Issuance for Services under Payments Agreement with Salzman Group
November 12, 2018
Kalytera Announces Progress with Cannabinoid-Based Compound for Treatment of Acute and Chronic Pain
September 27, 2018
Kalytera Announces Grant of Stock Options to Directors and Employees
September 24, 2018
Kalytera Therapeutics Provides Update for Lead Program in Prevention and Treatment of GVHD
September 20, 2018
Kalytera Reports Second Quarter 2018 Financial Results
August 30, 2018
Kalytera Provides Update on Arrangement with Former Shareholders of Talent Biotechs
August 24, 2018
View all News and Insights
Browse by Year
2018
2017
2016
2015
